The 1st International standard for transforming growth factor-β3 (TGF-β3)

Research output: Contribution to journalArticle


  • Meenu Wadhwa
  • Paula Dilger
  • Michelle Hamill
  • Sarah Gibbs
  • Guoping Wu
  • Jo Read
  • Tony Wyss-Coray
  • Hui Zhang
  • John Little
  • Katherine M Getliffe
  • Gao Kai
  • Weihong Wang
  • David Bender
  • Chris Bird
  • Alan B Heath
  • Anne Cooke
  • Robin Thorpe

External organisations

  • Biotherapeutics Group, NIBSC, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, UK.


One candidate preparation of human sequence recombinant transforming growth factor-β3 (TGF-β3) was formulated and lyophilized at NIBSC prior to evaluation in a collaborative study for its suitability to serve as an international standard. The preparation was tested by 8 laboratories using in vitro bioassays and immunoassays. The candidate preparation 09/234 was judged suitable to serve as an international standard based on the data obtained for biological activity and stability. On the basis of the results reported here, the preparation coded 09/234 was established by the WHO Expert Committee on Biological Standardisation (ECBS) as the WHO 1st IS for human TGF-β3 with an assigned value for TGF-β3 activity of 19,000 IU/ampoule.


Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalJournal of Immunological Methods
Issue number1-2
Publication statusPublished - 29 Jun 2012


  • Biological Assay, Humans, Immunoassay, Reference Standards, Transforming Growth Factor beta3, Journal Article